NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists.
BrIDGs program scientists collaborate with researchers to advance candidate therapeutics for both common and rare diseases into clinical testing. Selected researchers partner with NCATS experts to generate preclinical data and clinical-grade material through government contracts to use in Investigational New Drug (IND) applications to regulatory agencies, such as the Food and Drug Administration. Investigators do not receive grant funds through this program. In general, BrIDGs staff provide synthesis, formulation, pharmacokinetic and toxicology expertise and resources to its collaborators.
The goal of the TRND program is to encourage and speed the development of new treatments for rare conditions and neglected tropical infectious diseases with high unmet medical needs. TRND program scientists and their collaborators move new therapeutic candidates through preclinical testing, from lead optimization to submission of an IND application. On a case-by-case basis, TRND supports clinical testing to demonstrate safety and proof-of-concept of investigational drug effectiveness in patients. These efforts effectively “de-risk” therapeutic candidates and make them more attractive for adoption by outside partners.
Posted October 2015